Emerging drugs in the treatment of pancreatic cancer

Devalingam Mahalingam, Kevin R. Kelly, Ronan T. Swords, Jennifer Carew, Steffan T. Nawrocki, Francis J. Giles

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)311-328
Number of pages18
JournalExpert Opinion on Emerging Drugs
Volume14
Issue number2
DOIs
StatePublished - Jun 2009

Fingerprint

Pancreatic Neoplasms
gemcitabine
Pharmaceutical Preparations
Biological Factors
Therapeutics
Neoplasms
Mutation
Drug Therapy
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Mahalingam, D., Kelly, K. R., Swords, R. T., Carew, J., Nawrocki, S. T., & Giles, F. J. (2009). Emerging drugs in the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 14(2), 311-328. https://doi.org/10.1517/14728210902972502

Emerging drugs in the treatment of pancreatic cancer. / Mahalingam, Devalingam; Kelly, Kevin R.; Swords, Ronan T.; Carew, Jennifer; Nawrocki, Steffan T.; Giles, Francis J.

In: Expert Opinion on Emerging Drugs, Vol. 14, No. 2, 06.2009, p. 311-328.

Research output: Contribution to journalArticle

Mahalingam, D, Kelly, KR, Swords, RT, Carew, J, Nawrocki, ST & Giles, FJ 2009, 'Emerging drugs in the treatment of pancreatic cancer', Expert Opinion on Emerging Drugs, vol. 14, no. 2, pp. 311-328. https://doi.org/10.1517/14728210902972502
Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Emerging drugs in the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs. 2009 Jun;14(2):311-328. https://doi.org/10.1517/14728210902972502
Mahalingam, Devalingam ; Kelly, Kevin R. ; Swords, Ronan T. ; Carew, Jennifer ; Nawrocki, Steffan T. ; Giles, Francis J. / Emerging drugs in the treatment of pancreatic cancer. In: Expert Opinion on Emerging Drugs. 2009 ; Vol. 14, No. 2. pp. 311-328.
@article{5b7802ba58da43a1a445a58df4ebe021,
title = "Emerging drugs in the treatment of pancreatic cancer",
abstract = "Background: Pancreatic cancer is the fourth leading cause of cancer-related death in the US. However, there is a growing belief that novel biological agents could improve survival of patients with this cancer. Gemcitabine-based chemotherapy remains the cornerstone treatment for advanced pancreatic cancers. So far, the current targeted agents that have been used in combination with gemcitabine have failed to improve clinical outcomes. This failure may stem from the heterogeneous molecular pathogenesis of pancreatic cancers, which involves several oncogenic pathways and defined genetic mutations. Objective: The aims of this review are: i) to define the existing treatments available at present for patients with pancreatic cancers in the neo-adjuvant, adjuvant, locally advanced and metastatic settings; ii) to highlight the molecular heterogeneity of the cancers and the rationale for targeting specific oncogenic pathways; iii) to give an overview of targeted agents that may potentially have an impact in the treatment of pancreatic cancers. Conclusions: Molecular pathogenesis of pancreatic cancer involves several pathways and defined genetic mutations. Targeting these complex molecular pathways with a combination of novel biological and chemotherapeutic agents could potentially improve patient outcome.",
keywords = "Apoptosis and hedgehog pathway, EGFR, HDAC, IGF-1R, K-Ras, Pancreatic cancer, STAT3, Targeted therapies, VEGF",
author = "Devalingam Mahalingam and Kelly, {Kevin R.} and Swords, {Ronan T.} and Jennifer Carew and Nawrocki, {Steffan T.} and Giles, {Francis J.}",
year = "2009",
month = "6",
doi = "10.1517/14728210902972502",
language = "English",
volume = "14",
pages = "311--328",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Emerging drugs in the treatment of pancreatic cancer

AU - Mahalingam, Devalingam

AU - Kelly, Kevin R.

AU - Swords, Ronan T.

AU - Carew, Jennifer

AU - Nawrocki, Steffan T.

AU - Giles, Francis J.

PY - 2009/6

Y1 - 2009/6

N2 - Background: Pancreatic cancer is the fourth leading cause of cancer-related death in the US. However, there is a growing belief that novel biological agents could improve survival of patients with this cancer. Gemcitabine-based chemotherapy remains the cornerstone treatment for advanced pancreatic cancers. So far, the current targeted agents that have been used in combination with gemcitabine have failed to improve clinical outcomes. This failure may stem from the heterogeneous molecular pathogenesis of pancreatic cancers, which involves several oncogenic pathways and defined genetic mutations. Objective: The aims of this review are: i) to define the existing treatments available at present for patients with pancreatic cancers in the neo-adjuvant, adjuvant, locally advanced and metastatic settings; ii) to highlight the molecular heterogeneity of the cancers and the rationale for targeting specific oncogenic pathways; iii) to give an overview of targeted agents that may potentially have an impact in the treatment of pancreatic cancers. Conclusions: Molecular pathogenesis of pancreatic cancer involves several pathways and defined genetic mutations. Targeting these complex molecular pathways with a combination of novel biological and chemotherapeutic agents could potentially improve patient outcome.

AB - Background: Pancreatic cancer is the fourth leading cause of cancer-related death in the US. However, there is a growing belief that novel biological agents could improve survival of patients with this cancer. Gemcitabine-based chemotherapy remains the cornerstone treatment for advanced pancreatic cancers. So far, the current targeted agents that have been used in combination with gemcitabine have failed to improve clinical outcomes. This failure may stem from the heterogeneous molecular pathogenesis of pancreatic cancers, which involves several oncogenic pathways and defined genetic mutations. Objective: The aims of this review are: i) to define the existing treatments available at present for patients with pancreatic cancers in the neo-adjuvant, adjuvant, locally advanced and metastatic settings; ii) to highlight the molecular heterogeneity of the cancers and the rationale for targeting specific oncogenic pathways; iii) to give an overview of targeted agents that may potentially have an impact in the treatment of pancreatic cancers. Conclusions: Molecular pathogenesis of pancreatic cancer involves several pathways and defined genetic mutations. Targeting these complex molecular pathways with a combination of novel biological and chemotherapeutic agents could potentially improve patient outcome.

KW - Apoptosis and hedgehog pathway

KW - EGFR

KW - HDAC

KW - IGF-1R

KW - K-Ras

KW - Pancreatic cancer

KW - STAT3

KW - Targeted therapies

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=67649386620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649386620&partnerID=8YFLogxK

U2 - 10.1517/14728210902972502

DO - 10.1517/14728210902972502

M3 - Article

C2 - 19466902

AN - SCOPUS:67649386620

VL - 14

SP - 311

EP - 328

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -